BFS
PACB icon

Bradley Foster & Sargent’s Pacific Biosciences PACB Stock Holding History

Bradley Foster & Sargent’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,658
Closed -$126K – 436
2022
Q3 		$126K Buy
+21,658
New +$124K ﹤0.01% 415
2016
Q4 		– Sell
-25,000
Closed -$224K – 352
2016
Q3 		$224K Buy
+25,000
New +$209K 0.01% 319

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bradley Foster & Sargent's PACB Position: Q4 2022 in Review

Bradley Foster & Sargent sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 21,658 shares — an estimated $126K sold.

Bradley Foster & Sargent first reported a position in PACB in Q3 2016 and held it in 2 quarters. The position peaked at $224K in Q3 2016. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

  • Bradley Foster & Sargent reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
  • Bradley Foster & Sargent sold 21,658 Pacific Biosciences shares in Q4 2022, an estimated $126K.
  • Bradley Foster & Sargent first reported a position in Pacific Biosciences in Q3 2016 and held it in 2 quarters.
  • Bradley Foster & Sargent's Pacific Biosciences position peaked at $224K in Q3 2016.
  • 236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Bradley Foster & Sargent's 13F filing for Q4 2022, filed 14 Feb 2023.